SGC-SMARCA-BRDVIII is a potent and selective inhibitor targeting the bromodomains of the SWI/SNF chromatin remodeling complex, particularly SMARCA2 and SMARCA4. Its primary application lies in epigenetic research, where it is used to probe the biological roles of these ATP-dependent chromatin remodelers in gene regulation, cell differentiation, and cancer progression. Due to frequent mutations or loss of SMARCA4 in cancers such as small cell carcinoma of the ovary, hypercalcemic type (SCCOHT) and non-small cell lung cancer, SGC-SMARCA-BRDVIII serves as a valuable tool compound to study synthetic lethality—where inhibition of SMARCA2 in SMARCA4-deficient cells leads to selective cancer cell death. This makes it instrumental in validating SMARCA2 as a therapeutic target and in guiding the development of new anticancer drugs. It is widely used in cellular and biochemical assays to assess target engagement, pathway modulation, and phenotypic responses in disease models.